Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: HUMANGGP:010955 (
mda-7
)
464
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Melanoma differentiation associated gene-7/interleukin-24 (
mda-7
/IL-24), a cytokine belonging to the IL-10 family, displays cancer-specific apoptosis-inducing properties when delivered by a replication-incompetent adenovirus (Ad.
mda-7
) or as a GST-tagged recombinant protein (GST-
MDA-7
). Previous studies demonstrated that an adenovirus expressing M4, a truncated version of
MDA-7
/IL-24 containing amino acid residues 104-206, also induced similar cancer-specific apoptosis. We generated recombinant GST-M4 proteins and examined the potency of GST-
MDA-7
and GST-M4 on a panel of epidermal growth factor receptor (EGFR) wild type and mutant non-small cell lung carcinoma (NSCLC) cells either as a single agent or in combination with a reversible EGFR inhibitor,
Tarceva
. The combination of either GST-
MDA-7
or GST-M4 ( approximately 0.1 microM) and
Tarceva
(10 microM), at sub-optimal apoptosis-inducing concentrations synergistically enhanced growth inhibition and apoptosis induction over that observed with either agent alone. The combination treatment also augmented inhibition of EGFR signaling, analyzed by phosphorylation of EGFR and its downstream effectors AKT and ERK1/2, over that with single-agent therapy.
Tarceva
enhanced GST-
MDA-7
and GST-M4 toxicity in cells expressing mutated EGFR proteins that are resistant to the inhibitory effects of
Tarceva
. In total, these data suggest that combined treatment of NSCLC cells with an EGFR inhibitor can augment the efficacy of GST-
MDA-7
and GST-M4 and that the EGFR inhibitor
Tarceva
may mediate this combinatorial effect by inhibiting multiple tyrosine kinases in addition to the EGFR. This approach highlights a potential new combinatorial strategy, which may prove beneficial for NSCLC patients with acquired resistance to EGFR inhibitors.
...
PMID:Targeted combinatorial therapy of non-small cell lung carcinoma using a GST-fusion protein of full-length or truncated MDA-7/IL-24 with Tarceva. 1827 Sep 68
